Not Signed In -
Pyrimethamine |
Daraprim |
Clinical Trial: Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse
This study has been completed.
|
Purpose
To compare pyrimethamine and intravenous (IV) clindamycin vs. pyrimethamine and sulfonamides in the treatment of AIDS patients with central nervous system (CNS) Toxoplasma gondii.
| Condition | Treatment or Intervention |
|---|---|
| Toxoplasmosis, Cerebral HIV Infections | Drug: Pyrimethamine Drug: Clindamycin |
MedlinePlus related topics: AIDS; Abscesses; Brain Diseases; Neurologic Diseases; Parasitic Diseases; Toxoplasmosis
Study Type: Interventional
Study Design: Treatment, Dose Comparison
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Exclusion Criteria
Co-existing Condition: Patients with the following conditions are excluded:
- Opportunistic infection (Pneumocystis carinii pneumonia (PCP), cryptococcal meningitis) or other conditions (brain abscess) which would make treatment results difficult to interpret due to concurrent infection, disease, or therapy.
Patients with other opportunistic infections or brain diseases are excluded.
Patients with AIDS and cerebral toxoplasmosis.
Location Information
California
Palo Alto Med Foundation, Palo Alto, California, 94301, United States
More Information
Study ID Numbers: 021A
Record last reviewed: June 1989
Last Updated: October 13, 2004
Record first received: November 2, 1999
ClinicalTrials.gov Identifier: NCT00002064
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: June 1989
Last Updated: October 13, 2004
Record first received: November 2, 1999
ClinicalTrials.gov Identifier: NCT00002064
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Daraprim (Drug Digest)
- Pyrimethamine (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
